Legal & General Group PLC Annexon, Inc. Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

A detailed history of Legal & General Group PLC transactions in Annexon, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 13,870 shares of ANNX stock, worth $71,569. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,870

Previous 13,870 -0.0%

Holding current value

$71,569

Previous $82,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.49 - $7.2 $5,419 - $8,690	1,207 Added 9.53%	13,870 $82,000
Q2 2024 Aug 14, 2024	BUY	$4.33 - $6.79 $30,989 - $48,596	7,157 Added 129.99%	12,663 $62,000
Q1 2024 May 14, 2024	BUY	$4.03 - $7.81 $7,971 - $15,448	1,978 Added 56.07%	5,506 $39,000
Q4 2023 Feb 15, 2024	SELL	$1.63 - $4.63 $1,375 - $3,907	-844 Reduced 19.3%	3,528 $16,000
Q2 2023 Aug 14, 2023	BUY	$2.1 - $6.37 $9,181 - $27,849	4,372 New	4,372 $15,000
Q2 2022 Aug 22, 2022	SELL	$2.11 - $4.06 $15,660 - $30,133	-7,422 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$11.49 - $22.0 $15,431 - $29,546	1,343 Added 22.09%	7,422 $86,000
Q3 2021 Nov 15, 2021	BUY	$16.35 - $23.4 $49,327 - $70,597	3,017 Added 98.53%	6,079 $113,000
Q2 2021 Aug 12, 2021	SELL	$17.81 - $27.48 $4,808 - $7,419	-270 Reduced 8.1%	3,062 $69,000
Q1 2021 May 17, 2021	BUY	$22.0 - $35.01 $24,464 - $38,931	1,112 Added 50.09%	3,332 $93,000
Q4 2020 Feb 12, 2021	SELL	$20.81 - $30.55 $831,359 - $1.22 Million	-39,950 Reduced 94.74%	2,220 $55,000
Q3 2020 Nov 13, 2020	BUY	$17.5 - $30.23 $737,975 - $1.27 Million	42,170 New	42,170 $1.28 Million

Others Institutions Holding ANNX

# of Institutions

146

Shares Held

102M

Call Options Held

178K

Put Options Held

159K

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $246M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Annexon, Inc. Transaction History